|1.||Buchbinder, Aby: 4 articles (10/2014 - 12/2012)|
|2.||Horak, Ivan D: 4 articles (09/2011 - 03/2008)|
|3.||Sapra, Puja: 4 articles (09/2011 - 03/2008)|
|4.||Greenberger, Lee M: 4 articles (09/2011 - 03/2008)|
|5.||Mehlig, Mary: 3 articles (09/2011 - 03/2008)|
|6.||Kraft, Patricia: 3 articles (09/2011 - 03/2008)|
|7.||Ponzoni, Mirco: 2 articles (09/2011 - 10/2010)|
|8.||Pastorino, Fabio: 2 articles (09/2011 - 10/2010)|
|9.||Ribatti, Domenico: 2 articles (09/2011 - 10/2010)|
|10.||Malaby, Jennifer: 2 articles (10/2009 - 03/2008)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
10/01/2009 - "Here we evaluated the activity of EZN-2208, a water-soluble polyethyleneglycol-SN38 conjugate, in pre-clinical models of Burkitt's non-Hodgkin's lymphoma (NHL) (Raji and Daudi), and follicular NHL (DoHH2). "
10/01/2009 - "Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma."
10/01/2014 - "This Phase 1 study evaluated the safety, pharmacokinetics, and preliminary antitumor activity of EZN-2208 in children with relapsed or refractory solid tumors. "
12/15/2012 - "In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors. "
10/01/2009 - "In both an early-disease Raji model and an advanced-disease Daudi model, treatment with multiple doses of EZN-2208 resulted in 90% and 100% cures of animals, respectively (cure defined as no sign of tumors by gross observations at the termination of study). "
10/01/2014 - "EZN-2208 has demonstrated clinical tolerability and antitumor activity in adults with advanced solid tumors. "
04/01/2014 - "Preliminary proof-of-concept for modulation of HIF-1α protein in tumor biopsies following administration of EZN-2208 was observed. "
10/01/2014 - "EZN-2208 was generally well-tolerated and was associated with clinical benefit in patients with neuroblastoma."
10/01/2010 - "The antitumor activity of a water soluble pegylated SN38 drug conjugate, EZN-2208, was compared with CPT-11 (a prodrug for SN38) in preclinical models of human neuroblastoma. "
10/01/2010 - "EZN-2208 gave superior antitumor effects compared with CPT-11 in neuroblastoma xenografts. "
10/01/2010 - "EZN-2208 treatment always resulted in lack of tumor detection at the end of trials whereas only small therapeutic effects were observed with CPT-11, as assessed by luciferase assay or tumor size, or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. "
10/01/2010 - "In a neuroblastoma model resistant to doxorubicin, cisplatin, vincristine, fenretinide, and topotecan, EZN-2208 induced 100% curability. "
08/15/2015 - "Hypoxia-inducible factor-1α (HIF-1α) activation has been recently reported in APL, and EZN-2208 (PEG-SN38) is a compound with HIF-1α inhibitory function currently tested in clinical trials. "
10/01/2010 - "EZN-2208 was about 100-fold more potent than CPT-11 in vitro, by inducing apoptosis/necrosis and p53 expression and by reducing hypoxia-inducible factor (HIF)-1α/HIF-2α expression. "
|3.||Ethylene Glycol (Monoethylene Glycol)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)